Angina News and Research RSS Feed - Angina News and Research

Angina is chest pain or discomfort that occurs when an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also may occur in your shoulders, arms, neck, jaw, or back. It can feel like indigestion.
FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration approved Praluent (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. [More]
Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy. [More]
Scientists identify association between coronary heart disease and osteoporosis

Scientists identify association between coronary heart disease and osteoporosis

University of Southampton scientists have discovered a link between coronary heart disease and osteoporosis, suggesting both conditions could have similar causes. [More]
Full clinical trial feasible in refractory chronic angina pectoris

Full clinical trial feasible in refractory chronic angina pectoris

Results of the world's first publicly funded randomized controlled clinical trial of spinal cord stimulation, being presented today at the 12th World Congress of the International Neuromodulation Society, conclude that a fully powered clinical trial is feasible in refractory chronic angina pectoris, a disabling and persistent chronic pain condition. [More]
Glucose-control drug sitagliptin does not raise risk of cardiovascular events

Glucose-control drug sitagliptin does not raise risk of cardiovascular events

A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular events. [More]
Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia (lixisenatide) in adults with type 2 diabetes and high CV risk. [More]
Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD). [More]
Updated data from PROCLAIM national patient registry presented at 51st ASCO

Updated data from PROCLAIM national patient registry presented at 51st ASCO

Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies. [More]
Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015. [More]
Patients undergoing percutaneous coronary intervention at higher risk for sleep apnea

Patients undergoing percutaneous coronary intervention at higher risk for sleep apnea

Patients undergoing percutaneous coronary intervention (PCI), a coronary artery widening procedureused to treat heart disease, are at high risk for obstructive sleep apnea (OSA), according to new research presented at the 2015 American Thoracic Society International Conference. [More]
Global market for cardiac rhythm management devices worth $13 billion for 2015

Global market for cardiac rhythm management devices worth $13 billion for 2015

The global market for cardiac rhythm management devices such as pacemakers and defibrillators is worth about $13 billion for 2015, according to Kalorama Information. The market research publisher said the market has benefited from the demand to move to a more mobile, wireless and efficient system both within major health facilities and in the home treatment markets. There is also an increasing trend to upgrade to more portable devices and devices which have added benefits such as MRI compatibility. [More]
Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart attack, a blood clot in their heart stent (stent thrombosis), or even death. [More]
Aspirin use continues to surge among older adults in US

Aspirin use continues to surge among older adults in US

A national survey suggests that slightly more than half of the older adults in the United States are now taking a daily dose of aspirin, even though its use is not recommended by the Food and Drug Administration for most people who have not yet had a heart attack or stroke. [More]
Cedars-Sinai Heart Institute sets new national standard for most adult heart transplants

Cedars-Sinai Heart Institute sets new national standard for most adult heart transplants

The Cedars-Sinai Heart Institute completed 120 adult heart transplants and two adult heart-lung transplants in 2014, setting a new national standard for the most adult heart transplants performed in a single year. [More]
Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. [More]
Non-invasive imaging tests may predict healthy adults' future risk of heart attack, stroke or death

Non-invasive imaging tests may predict healthy adults' future risk of heart attack, stroke or death

Adding two non-invasive imaging tests to traditional cardiovascular disease risk factor assessment more precisely predicts a healthy patient's future risk of heart attack, stroke, or premature death, according to a study led by Icahn School of Medicine at Mount Sinai and published in the March 24 edition of the Journal of the American College of Cardiology. [More]
Study finds no statistical difference between CTA and functional stress tests

Study finds no statistical difference between CTA and functional stress tests

A new type of CT scan initially costs slightly less than the traditional stress test to diagnose blocked coronary arteries in patients with chest pain, but its lower cost did not translate into medical care savings over time, according to an analysis by Duke Medicine researchers. [More]
Anticoagulant drug bivalirudin shows mixed results in MATRIX trial

Anticoagulant drug bivalirudin shows mixed results in MATRIX trial

Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints--a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding--as compared to patients receiving standard anticoagulation therapy, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session. [More]
Using arm as access point for catheter-based heart procedures lowers risk of major bleeding, death

Using arm as access point for catheter-based heart procedures lowers risk of major bleeding, death

Patients with acute coronary syndrome undergoing coronary angiogram, a procedure used to assess blockages in the heart's arteries, had a significantly lower risk of major bleeding and death if their interventional cardiologist accessed the heart through an artery in the arm rather than the groin, according to research presented at the American College of Cardiology's 64th Annual Scientific Session. [More]
Study compares effectiveness of CT scan and traditional stress test in patients with chest pain

Study compares effectiveness of CT scan and traditional stress test in patients with chest pain

Patients with chest pain have similar rates of heart attacks and other major cardiac events within two years whether they were evaluated with a new type of CT scan or the traditional stress test, according to results presented today by Duke Medicine researchers at a meeting of the American College of Cardiology. [More]
Advertisement
Advertisement